03:30 PM EDT, 05/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lift our 12-month target by $4 to $177, valuing ATR at 28.2x our 2025 EPS estimate, a discount to ATR's five-year average forward P/E of 28.8x. Our multiple is a premium relative to packaging peers, which trade at an average forward P/E of 15.4x, but a less significant premium to the 25.3x average forward P/E for companies in the health care equipment & supplies industry, which we view as a relevant comparison given ATR's significant Pharma exposure (67% of 2024 adjusted EBITDA). We raise our 2025 EPS estimate by $0.39 to $6.28 and 2026's by $0.14 to $6.84. Strength in the Pharma segment continues to be a primary driver of our Strong Buy opinion, as high demand in central nervous system therapies, emergency medicines, and respiratory treatments drove Q1 core sales growth of 3% Y/Y, with proprietary drug delivery systems up 4%. The non-discretionary nature of many of the products in the Pharma segment should provide some shelter from macroeconomic headwinds if recessionary concerns materialize.